Nautilus Biotechnology (NAUT) Net Cash Flow (2020 - 2026)

Nautilus Biotechnology has disclosed Net Cash Flow across 7 years of filings, most recently posting -$1.5 million for Q2 2026.

• In Q2 2026, Net Cash Flow fell 219.77% year-over-year to -$1.5 million; the TTM figure through Jun 2026 stood at -$21.3 million (down 322.43% YoY), while the FY2025 annual figure was -$15.3 million, down 284.97% from the prior year.
• Net Cash Flow came in at -$1.5 million for Q2 2026 at Nautilus Biotechnology, down from $2.2 million in the prior quarter.
• In the past five years, Net Cash Flow ranged from a high of $23.2 million in Q4 2024 to a low of -$74.3 million in Q4 2022.
• Average Net Cash Flow over 5 years is -$9.6 million, with a median of -$1.2 million recorded in 2024.
• Year-over-year, Net Cash Flow sank 1613.38% in 2024 and soared 244.43% in 2025.
• Over 5 years, Net Cash Flow stood at -$74.3 million in 2022, then rose by 26.37% to -$54.7 million in 2023, then jumped by 142.48% to $23.2 million in 2024, then slumped by 149.43% to -$11.5 million in 2025, then soared by 87.29% to -$1.5 million in 2026.
• Per Business Quant data, the three most recent Net Cash Flow figures were -$1.5 million in Q2 2026, $2.2 million in Q1 2026, and -$11.5 million in Q4 2025.